Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 /CenExel is pleased to announce its partnership with Metsera, Inc.

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating ...

Cantor Fitzgerald initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage issued an overweight rating on the stock.

Guggenheim initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $ ...

On Tuesday, Cantor Fitzgerald began coverage of Metsera Inc (NASDAQ:MTSR) with an Overweight rating, highlighting the biotech company's potential in the obesity drug market. The firm's analyst ...